Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Palmetto Execs Explain Molecular Test Policies

Goal is to create a process to assess science and clinical value for molecular tests and LDTs

CEO SUMMARY: To create more transparency in the process clinical labs use to submit claims for genetic tests, molecular diagnostic tests, and for laboratory-developed tests (LDT), the nation’s largest Medicare Administrative Contractor (MAC) has proposed two new local coverage determinations (LCD). CMS has changed Palmetto GBA’s statement of work to include implementing a lab test …

Palmetto Execs Explain Molecular Test Policies Read More »

To access this post, you must purchase The Dark Report.

Comments

;

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.